ATE264324T1 - Substituierte biphenylisoxazolsulfonamide - Google Patents
Substituierte biphenylisoxazolsulfonamideInfo
- Publication number
- ATE264324T1 ATE264324T1 AT97915055T AT97915055T ATE264324T1 AT E264324 T1 ATE264324 T1 AT E264324T1 AT 97915055 T AT97915055 T AT 97915055T AT 97915055 T AT97915055 T AT 97915055T AT E264324 T1 ATE264324 T1 AT E264324T1
- Authority
- AT
- Austria
- Prior art keywords
- substituted
- biphenylisoxazolesulfonamides
- symbols
- co2r5
- nr8r9
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- -1 cycloalkenylalkyl Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/42—Benzene-sulfonamido pyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60397596A | 1996-02-20 | 1996-02-20 | |
| US75471596A | 1996-11-21 | 1996-11-21 | |
| US08/799,616 US5846990A (en) | 1995-07-24 | 1997-02-13 | Substituted biphenyl isoxazole sulfonamides |
| PCT/US1997/003956 WO1997029748A1 (en) | 1996-02-20 | 1997-02-20 | Substituted biphenyl isoxazole sulfonamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE264324T1 true ATE264324T1 (de) | 2004-04-15 |
Family
ID=27416891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97915055T ATE264324T1 (de) | 1996-02-20 | 1997-02-20 | Substituierte biphenylisoxazolsulfonamide |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5846990A (de) |
| EP (1) | EP0921800B1 (de) |
| JP (1) | JP2002500619A (de) |
| AT (1) | ATE264324T1 (de) |
| AU (1) | AU720458B2 (de) |
| CA (1) | CA2240043A1 (de) |
| DE (1) | DE69728673T2 (de) |
| ES (1) | ES2219762T3 (de) |
| WO (1) | WO1997029748A1 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| JPH09124620A (ja) | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| PL328571A1 (en) * | 1996-02-20 | 1999-02-01 | Bristol Myers Squibb Co | Methods of obtaining biphenylisoxazol sulphonamides |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6432994B1 (en) | 1997-04-28 | 2002-08-13 | Texas Biotechnology Corporation | Sulfonamides for treatment of endothelin-mediated disorders |
| DE69830069T3 (de) * | 1997-10-17 | 2012-02-09 | Ark Therapeutics Ltd. | Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel |
| DE19813354A1 (de) * | 1998-03-26 | 1999-09-30 | Bayer Ag | Arylphenylsubstituierte cyclische Ketoenole |
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| PT1094816E (pt) * | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| TW526202B (en) | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
| HK1039778A1 (zh) | 1999-03-19 | 2002-05-10 | Bristol-Myers Squibb Company | 制造联苯异恶唑基磺胺的方法 |
| EP1741713A3 (de) * | 1999-12-15 | 2009-09-09 | Bristol-Myers Squibb Company | Biphenyl Sulfonamide als zweierlei Angiotensin Endothelin Rezeptor Antagonisten |
| EP1244657B1 (de) * | 1999-12-31 | 2004-12-29 | Encysive Pharmaceuticals Inc. | Sulfonamide und ihre derivate, die die aktivität des endothelins modulieren |
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| US6639082B2 (en) * | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| MXPA03007397A (es) | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas. |
| WO2003055482A1 (en) * | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| US7335779B2 (en) * | 2002-03-08 | 2008-02-26 | Quonova, Llc | Modulation of pathogenicity |
| US7338969B2 (en) * | 2002-03-08 | 2008-03-04 | Quonova, Llc | Modulation of pathogenicity |
| AU2003243921B2 (en) * | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| AU2003300014A1 (en) * | 2002-10-10 | 2004-05-04 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
| GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
| US7273866B2 (en) * | 2002-12-20 | 2007-09-25 | Bristol-Myers Squibb Company | 2-aryl thiazole derivatives as KCNQ modulators |
| US6933308B2 (en) * | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
| US20070196340A1 (en) * | 2003-05-06 | 2007-08-23 | Aldo Ammendola | Modulation of Pathogenicity |
| CA2528834A1 (en) * | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| JP2007516180A (ja) * | 2003-07-02 | 2007-06-21 | スゲン，インコーポレイティド | ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類 |
| DE10337497A1 (de) | 2003-08-14 | 2005-03-10 | Bayer Cropscience Ag | 4-Biphenylsubstituierte-Pyrazolidin-3,5-dion-Derivate |
| PT1723128E (pt) * | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| US7854924B2 (en) * | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| CA2557999C (en) | 2004-03-30 | 2013-11-12 | Ilypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| JP2009500378A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| KR20080024211A (ko) * | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | 디시클로알킬 우레아 글루코키나제 활성제 |
| BRPI0612996A2 (pt) * | 2005-07-14 | 2010-12-14 | Novo Nordisk As | ativadores de urÉia glucocinase |
| JP2009510233A (ja) * | 2005-09-30 | 2009-03-12 | レリプサ， インコーポレイテッド | 架橋シェルを有するコア−シェルコンポジットを製造する方法および該方法によって生じたコア−シェルコンポジット |
| AU2006299449B2 (en) | 2005-09-30 | 2013-07-04 | Relypsa, Inc. | Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
| BRPI0708507A2 (pt) * | 2006-03-03 | 2011-05-31 | Torrent Pharmaceuticals Ltd | Novos antagonistas de receptores de dupla ação (dara) para os receptores at1 eta |
| US8138185B2 (en) * | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
| AU2008204530B2 (en) * | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| US20100104527A1 (en) * | 2008-08-22 | 2010-04-29 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| WO2010022380A2 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
| EP3431094B1 (de) * | 2008-08-22 | 2022-12-07 | Vifor (International) Ltd. | Vernetzte kationenaustauschpolymere, zusammensetzungen und verwendung in der behandlung von hyperkaliämie |
| JP2014514257A (ja) * | 2011-03-03 | 2014-06-19 | ユニバーシテーテ デス ザールランデス | 選択的１７ベータ−ヒドロキシステロイドデヒドロゲナーゼ２型阻害剤としてのビアリール誘導体 |
| CN104822383A (zh) | 2012-10-08 | 2015-08-05 | 瑞立普萨公司 | 治疗高血压和高血钾症的钾结合剂 |
| AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CA3222721A1 (en) * | 2021-07-09 | 2023-01-12 | Nadia Nasser PETERSEN | New selective angiotensin ii compounds |
| WO2023224963A1 (en) * | 2022-05-16 | 2023-11-23 | Aria Pharmaceuticals, Inc. | Dual-acting angiotensin and endothelin receptor antagonists |
| CN115010621B (zh) * | 2022-07-21 | 2023-11-03 | 山东百启生物医药有限公司 | 一种4-溴-3-甲基苯甲腈的合成方法 |
| CN115677511B (zh) * | 2022-10-26 | 2024-06-21 | 南通华祥医药科技有限公司 | 一种2,2-二氟丙胺盐酸盐的合成方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB804036A (en) * | 1956-03-02 | 1958-11-05 | Hoffmann La Roche | A process for the manufacture of a sulphanilamide of the isoxazole series |
| CH364506A (de) * | 1956-09-04 | 1962-09-30 | Shionogi & Co | Verfahren zur Herstellung des therapeutisch wirksamen 3-Sulfanilamido-5-methyl-isoxazols |
| US2888455A (en) * | 1956-09-04 | 1959-05-26 | Shionogi & Co | New sulfonamide and process for producing the same |
| DE1059459B (de) * | 1956-09-04 | 1959-06-18 | Shionogi & Co | Verfahren zur Herstellung des therapeutisch wertvollen 3-Sulfanilamido-5-methylisoxazols |
| GB897440A (en) * | 1960-02-08 | 1962-05-30 | Shionogi & Co | Improvements in or relating to sulfonamides |
| GB1473433A (de) * | 1975-10-09 | 1977-05-11 | Banyu Pharmaceutical Co Ltd Hi | |
| US4415496A (en) * | 1981-03-23 | 1983-11-15 | Merck & Co., Inc. | Bicyclic lactams |
| EP0076072B1 (de) * | 1981-09-24 | 1987-05-13 | BEECHAM - WUELFING GmbH & Co. KG | Sulfonamide |
| US4661479A (en) * | 1982-02-19 | 1987-04-28 | Merck And Co., Inc. | Bicyclic lactams as antihypertensives |
| EP0194548A3 (de) * | 1985-03-12 | 1988-08-17 | Dr. Karl Thomae GmbH | Neue Sulfonylaminoäthylverbindungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| CA2005741C (en) * | 1988-12-26 | 1998-06-02 | Hiroyoshi Hidaka | Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity |
| US5082838A (en) * | 1989-06-21 | 1992-01-21 | Takeda Chemical Industries, Ltd. | Sulfur-containing fused pyrimidine derivatives, their production and use |
| DE122010000024I1 (de) * | 1990-02-19 | 2010-07-08 | Novartis Ag | Acylverbindungen |
| CA2079343A1 (en) * | 1990-03-30 | 1991-10-01 | Eric E. Allen | Substituted pyrazoles, isoxazoles and isothiazoles |
| US5236928A (en) * | 1991-03-19 | 1993-08-17 | Merck & Co., Inc. | Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists |
| TW270116B (de) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| PL176250B1 (pl) * | 1991-11-05 | 1999-05-31 | Smithkline Beecham Corp | Sposób wytwarzania pochodnych indanu |
| SE9103397D0 (sv) * | 1991-11-18 | 1991-11-18 | Kabi Pharmacia Ab | Nya substituerade salicylsyror |
| TW224462B (de) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
| US5378715A (en) * | 1992-02-24 | 1995-01-03 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
| TW215434B (de) * | 1992-03-07 | 1993-11-01 | Hoechst Ag | |
| US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| WO1993023404A1 (en) * | 1992-05-19 | 1993-11-25 | Immunopharmaceutics, Inc. | Compounds that modulate endothelin activity |
| TW287160B (de) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
| EP0617001B1 (de) * | 1993-03-19 | 2000-01-26 | Merck & Co. Inc. | Phenoxyphenylessigsäurederivate |
| FI941826A7 (fi) * | 1993-04-21 | 1994-10-22 | Takeda Chemical Industries Ltd | Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi |
| TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| ES2154277T3 (es) * | 1993-07-15 | 2001-04-01 | Hoffmann La Roche | Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina. |
| US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
| GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| CA2168154A1 (en) * | 1995-02-06 | 1996-08-07 | Natesan Murugesan | Substituted biphenyl sulfonamide endothelin antagonists |
| DE19509950A1 (de) * | 1995-03-18 | 1996-09-19 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
| NZ306734A (de) * | 1995-04-04 | 2000-01-28 | Texas Biotechnology Corp | |
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
| PL328571A1 (en) * | 1996-02-20 | 1999-02-01 | Bristol Myers Squibb Co | Methods of obtaining biphenylisoxazol sulphonamides |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
-
1997
- 1997-02-13 US US08/799,616 patent/US5846990A/en not_active Expired - Lifetime
- 1997-02-20 AT AT97915055T patent/ATE264324T1/de not_active IP Right Cessation
- 1997-02-20 WO PCT/US1997/003956 patent/WO1997029748A1/en not_active Ceased
- 1997-02-20 CA CA002240043A patent/CA2240043A1/en not_active Abandoned
- 1997-02-20 AU AU22098/97A patent/AU720458B2/en not_active Ceased
- 1997-02-20 EP EP97915055A patent/EP0921800B1/de not_active Expired - Lifetime
- 1997-02-20 ES ES97915055T patent/ES2219762T3/es not_active Expired - Lifetime
- 1997-02-20 JP JP52962097A patent/JP2002500619A/ja not_active Ceased
- 1997-02-20 DE DE69728673T patent/DE69728673T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU720458B2 (en) | 2000-06-01 |
| DE69728673T2 (de) | 2005-03-31 |
| CA2240043A1 (en) | 1997-08-21 |
| JP2002500619A (ja) | 2002-01-08 |
| EP0921800A4 (de) | 2000-12-06 |
| DE69728673D1 (de) | 2004-05-19 |
| EP0921800B1 (de) | 2004-04-14 |
| EP0921800A1 (de) | 1999-06-16 |
| US5846990A (en) | 1998-12-08 |
| ES2219762T3 (es) | 2004-12-01 |
| WO1997029748A1 (en) | 1997-08-21 |
| AU2209897A (en) | 1997-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69728673D1 (de) | Substituierte biphenylisoxazolsulfonamide | |
| FI954008A0 (fi) | Substituoituja bifenyyli-isoksatsolisulfoniamideja | |
| AR002028A1 (es) | Bifenilsulfonamidas substituidas, antagonista de la endotelina, y las composiciones farmaceuticas que las contienen. | |
| MY109004A (en) | Sulfonamide endothelin antagonists | |
| TW370450B (en) | Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives | |
| DK0569193T3 (de) | ||
| DK0663907T3 (da) | Fremgangsmåde til fremstilling af taxanderivater | |
| HU9301452D0 (en) | Amino-pyrimidine derivatives of insecticidal, acaricidal and fungicidal effects | |
| DK0915866T3 (da) | Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre | |
| EP0605726A4 (en) | 1,3-oxazin-4-one derivative, herbicide containing the same, and novel intermediate for producing the same. | |
| EP0945764A3 (de) | Fotoresistzusammensetzung | |
| NO306062B1 (no) | Syremellomprodukter til bruk ved fremstilling av taxanderivater | |
| WO2002000638A8 (en) | Substituted phthalides as anti-convulsive drugs | |
| CA2137961A1 (en) | Cyclic depsipeptides having 18 ring atoms, and their use for combating endoparasites | |
| EG21122A (en) | Novel hydrazincarboxylate miticides and incecticides | |
| IL115833A0 (en) | Halogenated esters useful as intermediates for insecticides | |
| ES2105314T3 (es) | Derivados de (amino-3 fenil)-1 etanosulfonato de alquilamonio opticamente activos, su preparacion y su utilizacion. | |
| GB9309795D0 (en) | Preparation of flouro-compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |